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INTRODUCTION
Mastitis
Mastitis is an inflammatory process of the udder 
in response to an intramammary infection, which 
can have either a clinical or subclinical outcome. In 
clinical mastitis, the cow is generally ill (e.g. fever, 
depression) and the affected udder quarter shows red-
ness and swelling. Milk derived from the inflamed 
quarter often looks abnormal. In contrast, no visual 
abnormalities are present in the milk derived from 
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an udder quarter with subclinical mastitis. Therefore, 
subclinical mastitis can easily be diagnosed through 
measuring an increase of inflammatory cells (somatic
cell count, SCC) in the milk (Sadek et al., 2017; 
Pyörälä, 2003). Other diagnostic methods are the 
California mastitis test (CMT) and in-line electrical 
conductivity tests (IECT) (Ruegg, 2002). The CMT 
involves a colorimetric reaction with the DNA of the 
inflammatory cells in milk, whereas the IECT mea-
sures the electric resistance of milk.
The main cause of mastitis is the penetration of 
bacteria, yeasts and/or fungi through the teat orifice. 
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Today, more than hundred organisms are known to 
cause bovine mastitis (De Vliegher, 2017). Two main 
approaches are used to stratify these pathogens. A 
first classification is cow-adapted versus environ-
mental pathogens. Cow-adapted germs survive and 
propagate mainly on the animal and are transmitted 
through direct or indirect contact. The most important 
cow-related bacteria are: non-aureus Staphylococci 
spp., Staphylococcus aureus (S. aureus) and esculin-
positive cocci. Their prevalence in Flanders is shown 
in Table 1 (Piepers et al., 2007). Other important 
cow-adapted bacteria are Streptococcus dysgalactiae 
(S. dysgalactiae), S. agalactiae and Trueperella pyo-
genes, although their prevalence is significantly lower 
(Gill et al., 2006; Piepers et al., 2007) (Table 1). In 
contrast, environmental germs survive mainly in the 
stable. These pathogens are harder to eradicate and 
are therefore considered more important than the cow-
adapted germs. Escherichia coli (E. coli), Klebsiella 
and S. uberis infections are most common and arise 
from manure, wood shavings and straw, respectively 
(De Vliegher, 2017; Gonggrijp et al., 2017). A sec-
ond classification differentiates ‘major’ from ‘minor’ 
pathogens. Major pathogens cause a high increase in 
milk SCC and severe clinical mastitis, whereas these 
characteristics are rather mild in so-called minor 
pathogens. In contrast to the first classification, this 
approach does not include the spread of the different 
pathogens on a dairy farm. Although the latter aspect 
is important in breaking the transmission cycle, the 
first approach is internationally more preferred (De 
Vliegher, 2017).
The data summarized in Table 1 (Piepers et al., 
2007) probably have become outdated, as the percent-
age of cow-adapted infections can be expected to have 
decreased during the past decade due to more effec-
tive control campaigns in Flanders. Indeed, compared 
to the distribution of the main udder pathogens isolat-
ed from clinical milk samples in 2014 (data from the 
Milk Control Centre of Flanders (MCC Vlaanderen)), 
the following two observations are important: 1. a de-
crease in the cow-adapted non-aureus Staphylococci 
spp. and S. aureus from 19.1% to 10.6% and 56.6% 
to 7.8%, respectively; 2. an increase to 18.1% and 
18.7% for S. uberis and E. coli, respectively. These 
results indicate that in Flanders, environmental-bound 
pathogens have become more important than cow-
adapted pathogens.
Bovine mastitis is typically treated with antibio-
tic preparations, which are administered intramam-
marily. A division between preparations for dry and 
lactating cows is consistent in the currently used 
drugs. In this article however, the possible applica-
tion of phages and phage-derived endolysins in the 
future treatment of bovine mastitis is focussed. Cur-
rent treatments have been described by Royster E. and 
Wagner S. (2015). 
Bacteriophages and phage-derived endolysins
Bacteriophages, or shortly phages, are viruses that 
infect bacteria. Each phage can infect only one bacte-
rial species (or even strain) because it recognizes an 
adhesion molecule on the cell wall of the bacterium. 
When the phage is attached, it infects its host by in-
jecting its genetic material through the production of 
endolysins. These endolysins are enzymes, which are 
capable of digesting the bacterial cell wall. Subse-
quently, there are two possibilities: 1. the phage ge-
nome can pass a lysogenic cycle, in which the genome 
is incorporated into the bacterial DNA (prophage) 
and will replicate together with the bacterium, 2. the 
phage genome can start a lytic cycle, in which it uses 
the bacterial replication mechanisms to multiply its 
DNA (Figure 1). The genome then assembles with 
the viral proteins to create a new virion. Due to the 
massive production of virus particles, the bacterium 
eventually undergoes lysis. It is this feature which 
gives phages their ability to kill bacteria and there-
fore, they are proposed as an alternative to antibiotics. 
Phage-derived endolysins have also been suggested 
as a novel antimicrobial agent, because of their ability 
to lyse bacterial cell walls (Weber-Dąbrowska, 2016).
The One Health Initiative 
The One Health Initiative is a movement to forge 
co-equal, all-inclusive partnerships between physi-
cians, veterinarians, and other scientific-health related 
experts, recognizing that the health of people is con-
nected to the health of animals and the environment 
(http://www.onehealthinitiative.com/). The overuse 
of antibiotics in dairy farming leads to resistant bac-
teria and antimicrobial residues in milk (Oliver et al., 
Table 1. Prevalence of mastitis and the isolated bacteria 
in Flemish dairy farms from 2000 till 2002 (Piepers et 
al., 2007).
 
 2000 2001 2002 Overall
Number of cows 16,432 16,270 11,965 44,667
sampled 
% culture 39.0 41.7 43.0 41.1
positive cows 
Number of 65,728 65,080 47,860 178,668
quarters sampled 
No. Of culture- 10,602 11,236 8,637 30,475
positive samples 
% quarters culture-
positive for:    
Staphylococcus aureus 19.1 19.1 16.6 18.4
Esculine-positieve cocci 15.5 14.8 18.0 16.0
Streptococcus dysgalactiae 2.8 2.4 1.8 2.4
Streptococcus agalactiae 0.3 0.3 0.3 0.3
non-aureus staphylococci 56.6 57.5 57.4 57.2
Corynebacterium bovis 0.9 1.0 0.6 0.8
Coliforms 1.0 0.6 0.9 0.8
Contaminated samples 2.9 3.4 4.0 3.4
Other 1.0 1.0 0.3 0.8
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2012). If zoonotic pathogens become resistant, they 
can no longer be treated with conventional antibiotics 
when causing disease in humans. Residues of antimi-
crobial agents in milk and/or meat cause an increase 
of resistance genes in the commensal intestinal flora. 
If this resistance is plasmid-mediated, the intestinal 
flora is considered a source of resistance to possible 
pathogens (Carattoli et al., 2013).
Methicillin resistant S. aureus (MRSA) is known 
to cause mastitis, but also skin, soft tissue, bone, joint 
and implant infections, pneumonia and septicemia in 
both humans and animals. Approximately 20-30% of 
the human population carries MRSA asymptomatical-
ly, resulting from nosocomial or community-acquired 
transmissions. An important transmission route of 
community-acquired MRSA is through contact with 
intensively antibiotic-treated livestock. Close con-
tact with veal calves and pigs is a major risk factor 
for the transmission of livestock-associated MRSA 
to humans, because its prevalence is highest in these 
production animal sectors. In veterinary medicine, 
MRSA causes its most significant economic losses in 
the context of bovine mastitis (Holmes et al., 2011; 
Bosch et al., 2013).
A MINI-REVIEW OF THE BACTERIOPHAGE 
AND BOVINE MASTITIS LITERATURE
Since bacteriophages and phage-derived endoly-
sins were first proposed as a new potential antimicro-
bial drug in the treatment of bovine mastitis, promis-
ing literature has been published. For this mini-review, 
the results from approximately ten international peer-
reviewed papers are included. Although in vitro and 
in vivo tests with bacteriophages or phage-derived 
endolysins have only seldom been reported to treat 
bovine mastitis, this strategy has been intensively dis-
cussed over the past five years, which is indicative 
of the current and growing interest in bacteriophages 
and endolysins as alternatives for the traditional anti-
microbial agents.
In vitro and in vivo evaluation of bacteriophages 
in the context of bovine mastitis
Since 2010, several lytic phages derived from 
mastitis-affected cows have been proposed as poten-
tial therapeutic drugs (Han et al., 2013; Kwiatek et al., 
2012). The phages are able to effectively infect and 
kill bovine S. aureus including methicillin-resistant 
strains in vitro. Both bacteriophages are morphologi-
cally classified as Myoviridae and exhibit 1. rapid 
adsorption, i.e. the time needed for free phages to 
attach to the bacterium, 2. a short latent period, i.e. 
the time needed for lytic infection, and 3. a relatively 
small burst size, i.e. the average number of phages 
needed to cause bacterial lysis. Due to these three 
characteristics, the bacteriophages have been found 
eligible for therapeutic use. Another S. aureus bac-
teriophage (SPW-phage), also belonging to the Myo-
viridae family, has recently been isolated from lactat-
ing dairy cattle (Li et al., 2014). The three previously 
mentioned characteristics were likewise evaluated, 
whereby this SPW-phage may indeed have a potential 
use in future S. aureus mastitis therapy.
Recently, a cocktail consisting of four different 
bacteriophages has been proposed against E. coli 
through several in vitro tests (Porter et al., 2016). A 
3.3 to 5.6 log reduction of growth in raw milk was ob-
served when E. coli was co-incubated with this phage 
cocktail for twelve hours. Moreover, bacterial growth 
decreased with 1.6 × 10³ CFU/mL (colony forming 
Figure 1. The lysogenic and lytic cycle of bacteriophages. The lysogenic and lytic cycle can pass into one another 
(https://kullabs.com/classes/subjects/units/lessons/notes/note-detail/8287).
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units/mL) when tested against a mastitis-derived E. 
coli strain.
A phage K solution was administered intramam-
marily (1.25 x 1011 PFU/mL (plaque forming units/
mL)) to 24 lactating Holstein cows with a persistent S. 
aureus infection (Gill et al., 2006). While none of the 
negative control saline-treated quarters were cured, S. 
aureus could not be isolated in only three of the eigh-
teen phage-treated quarters samples, which were con-
secutively collected at 2 to 7 days, 9 to 14 days, 16 to 
21 days, and 23 to 28 days after the end of local phage 
treatment. The success rate of this phage K therapy is 
therefore regarded as limited.
A selected phage cocktail for the treatment of S. 
aureus-associated (Newbould 305) bovine mastitis 
has recently been tested in vitro and in a mouse model 
(Breyne et al., 2017). First, different cultures were 
verified in the presence or absence of IgG and the 
phage cocktail. Staphylococcus aureus could not be 
isolated from any of these cultures to which the phage 
cocktail was added, whether or not in the presence of 
IgG. These promising in vitro results were partly con-
firmed in an in vivo pilot study using a mouse model 
for bovine mastitis. Mammary glands of lactating 
mice were inoculated with the same bovine masti-
tis isolate (N305) of S. aureus. Subsequently, a first 
group of mice was inoculated intramammarily with 
cefalonium, a first-generation cephalosporin (used as 
positive control). A second group of mice received no 
treatment, but only saline (negative control). A third 
group was injected with the phage cocktail. Breyne et 
al. (2017) reported that S. aureus could not be isolated 
from the mice which were injected with cefalonium. 
In contrast, S. aureus was still present in the phage-
treated group although the number of colony forming 
units (CFU) was significantly lower when compared 
to the negative control group. In addition, a clinical 
score was given to the different mammary glands af-
ter infection. Both the cefalonium and phage-treated 
groups scored significantly better than the negative 
control group.
In vitro and in vivo evaluation of phage-derived 
endolysins in the context of bovine mastitis
In a study by Zhou et al. (2017), a recombinant, 
lytic enzyme (LysKΔamidase) was constructed out 
of a staphylococcal phage lysin, in which a broad 
lytic activity of LysKΔamidase was observed against 
137 methicillin-resistant and methicillin-susceptible 
staphylococcal strains isolated from human hospital 
patients and cows with bovine mastitis. In addition, 
this lytic enzyme was also found to disrupt the nor-
mal structure of biofilms, which are protective struc-
tures produced by bacteria (i.e. S. aureus) that consist 
of DNA, proteins and carbohydrates. The in vitro 
potential of endolysins was demonstrated to combat 
MRSA and other antimicrobial-resistant, biofilm-
forming staphylococcal strains associated with bovine 
mastitis.
In a study by Donovan et al. (2006), an endolysin 
derived from a S. aureus bacteriophage phi11 was pu-
rified and its effectiveness was demonstrated against 
S. aureus and non-aureus staphylococci. Its lytic ac-
tivity was maintained at the pH (6.7) and Ca2+ con-
centration (3 mM) of milk, making phi11 endolysin a 
potential candidate as antimicrobial protein.
In a study by Fan et al. (2016), another recom-
binant endolysin (Trx-SA1) from a S. aureus bacte-
riophage was derived by cloning it into the pET-32a 
bacterial expression vector. Subsequently, an efficacy 
trial of its effectiveness against bovine mastitis was 
conducted. When Trx-SA1 was added to the host bac-
teria in early growth stages, a complete bacterial ly-
sis was observed after nine hours. Preliminary results 
of a proof-of-concept therapeutic trial in cow udders 
showed that Trx-SA1 could effectively control mild 
clinical mastitis caused by S. aureus. 
Phage-derived λSA2 and B30 endolysins were 
tested in vitro and in a mouse mastitis model against 
bovine streptococci (Schmelcher et al., 2015). Lyt-
ic activities were observed to be optimal at ionic 
strengths, pH, and Ca2+ concentration consistent with 
those in cow milk. Moreover, λSA2-endolysins were 
demonstrated to reduce in vitro the amount of S. aga-
lactiae, S. dysgalactiae and S. uberis in cow milk by a 
log 2, 3.5, and 4 CFU/mL, respectively. Interestingly, 
although the B30 endolysin alone turned out to be less 
effective, a strong synergy appeared with the λSA2-
endolysin. When further tested in a mouse model for 
bovine mastitis, a significant decrease in CFU was 
observed after intramammary inoculation of these en-
dolysins in vivo. 
CRITICAL COMMENTS AND FUTURE PROS-
PECTS 
With only about ten promising in vitro and few in 
vivo studies reported till date, more research should 
be performed, especially in vivo, on the clinical ap-
plicability of either bacteriophages or their endolysins 
for the curative treatment of udder infections. Never-
theless, it may be summarized that most of these cur-
rent experiments show the effectiveness -at least in 
vitro- of phage therapy against S. aureus. There is an 
urgent demand for alternative therapies against this 
Gram-positive mastitis pathogen, because staphylo-
coccal intramammary infections are typically diffi-
cult to combat with classic antibiotics (Holmes et al., 
2011). Persistence of this germ in the mammary gland 
results in chronic, subclinical mastitis. In addition, re-
sistance against S. aureus is quickly established and 
persistent (Kadlec et al., 2012). 
Recently, several researchers have claimed that 
promising candidate bacteriophages and endolysins 
should now be tested in vivo to evaluate the effects of 
this novel treatment strategy in mammary gland of ro-
dents, but preferably in the target species i.e. the cow 
(Schmelcher et al., 2015; Porter et al., 2016). How-
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ever, even if the envisaged phage therapy confirms to 
be promising in these follow-up studies, several prac-
tical hurdles will raise during its development. It is 
known that raw milk inhibits staphylococcal phage K 
proliferation due to the formation of bacterial clusters 
associated with fat globules and/or the presence of 
IgG (O’Flaherty et al., 2005; Tanji et al., 2015). In ad-
dition, Phage K has been reported to cause an increase 
in the SCC of healthy quarters (Gill et al., 2006). Most 
strains belonging to the group of Gram-positive mas-
titis pathogens are also known to cause biofilms, a 
property associated with their difficult eradication by 
traditional antimicrobial drugs. It should be remarked 
that biofilm-formation also occurs in some Gram-nega- 
tive mastitis-causing bacteria such as Klebsiella. As 
mentioned above, phages and endolysins have been 
described to have the unique characteristic to digest 
these protective structures and are expected to be able 
to infect and lyse these problematic biofilm-forming, 
mastitis-causing bacteria (Latka et al., 2017; Zhou 
et al. 2017; Gerstmans et al. 2016; Gutiérrez et al., 
2014). 
Although some bacteria can be naturally resistant 
to bacteriophages due to the lack of required adhe-
sion molecules on their bacterial cell wall, induced 
resistance has not yet been described. If resistance 
would nevertheless occur, supplementing the phage 
therapy with endolysins could be a useful tactic. Due 
to the broader spectrum of action, resistance selec-
tion among the pathogens against the used phage type 
may be expected to be counteracted. Still, it has been 
stated that phage therapy could give rise to antibiotic 
resistance as bacteriophage therapy is not capable of 
breaking down plasmids (Colavecchio et al., 2017). 
After lysis, these plasmids could easily be taken up by 
other bacteria. If they contain resistance genes, then 
this induced resistance may spread between the sur-
viving bacteria (De Vliegher, 2017). 
In addition, in the in vivo and some in vitro stud-
ies mentioned above, only a reduction of the bacte-
rial count was observed, not a complete killing. This 
incomplete lysis of bacteria confirms the suboptimal 
effectiveness of current bacteriophages as well as 
phage-derived endolysins, even after enhancement of 
the latter by genetic engineering. Moreover, it should 
be noted that the delay time between experimental 
infection and administration of either bacteriophages 
or phage-derived endolysins in the used mouse mas-
titis model is very short, i.e. typically thirty minutes. 
Consequently, this set-up probably does not allow the 
mastitis pathogens to enter intracellularly nor to form 
biofilms. These experiments should be adapted to pro-
vide more relevant conditions for bovine mastitis as 
occurring on dairy farms. 
A treatment consisting of only one bacteriophage 
can never provide a broad-spectrum effect due to the 
species specificity inherent to phages (Nilsson, 2014). 
In contrast, for endolysins, the spectrum can be en-
hanced through genetic engineering. Indeed, endoly-
sins derived from bacteriophages that target Gram-
positive bacteria feature a modular design, consisting 
of enzymatically active domains and cell wall binding 
domains. This modular architecture enables the crea-
tion of chimeric fusion proteins with novel enzymatic 
and antimicrobial properties. In two parallel recent 
studies by Becker et al. (2016) and Rodríguez-Rubio 
et al., (2016), an engineered staphylolytic and strepto-
lytic fusion protein have been reported, respectively, 
with improved activities. Furthermore, the additional 
fusion to positively charged peptides significantly 
enhanced both the ability to kill intracellular masti-
tis pathogens and biofilm eradication, and reduced 
the incidence of resistant strain development against 
these engineered endolysins. It is therefore important 
to pursue research for more potent, novel bacterio-
phages and to genetically improve their derived en-
dolysins, to obtain an effective and fast-acting engi-
neered fusion endolysins with broad spectrum effect 
and a minimal induction of resistance. 
If phage therapy consists of applying only one 
phage type, the treatment is targeted against one spe-
cific type of bacterium. For the application in veteri-
nary practice however, it is more interesting to obtain 
a broader spectrum of activity. Bacteriological culture 
of milk samples from dairy cows is not done routinely 
and includes an additional cost for the dairy farmer. 
It may therefore be useful to develop cocktails con-
sisting of different bacteriophages or to supplement 
the phage therapy with endolysins. The expansion 
of the working spectrum has already been tested and 
confirmed by two recent studies (Porter et al., 2016; 
Breyne et al., 2017). The main disadvantage of the 
classical endolysins remains their Gram-positive 
spectrum. Despite the lack of potential to kill Gram-
negative germs, it should be emphasized that most of 
the problematic (intracellular and biofilm-forming) 
mastitis pathogens are indeed Gram-positive bacteria 
(Piepers et al., 2007). Moreover, as already demon-
strated in human medicine, artificial modification of 
existing endolysins, so-called Artilysins® (Lysando 
AG, Germany), may provide a broader spectrum of 
activity. These Artilysins® specifically attack Gram-
negative bacteria (Gerstmans et al., 2017). In addi-
tion, it has been demonstrated that artilysation of cur-
rently known endolysins also improves the lytic activ-
ity against Gram-positive germs (Rodríguez-Rubio et 
al., 2016). 
From the point of view of the dairy practitioner, 
a broad spectrum, long-acting, intramammary prepa-
ration is needed if phage and/or endolysin therapy is 
envisaged to be used in the local treatment of bovine 
mastitis. The principal advantage gained from a novel 
phage/endolysin cocktail would be the reduced use 
of antibiotics, more specifically, those that are criti-
cal for human health. Residues in milk may then be 
avoided, implying that the dairy farmer does not have 
to discard milk derived from phage-treated animals 
as is now obligatory for antibiotic-treated animals. It 
can also be noted that the in vivo therapeutic concen-
tration and the treatment interval are unknown fac-
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tors that depend on the type of bacteriophages and/or 
endolysins used. A pharmacokinetic study was con-
ducted, in which bacteriophage therapy was tested in 
subclinical S. aureus mastitis in lactating dairy cattle 
(Gill et al., 2006). Phage K persisted 36 hours within 
an infused quarter, but the effective concentration was 
significantly lower than predicted by simple dilution 
in produced milk. This implicates that more pharma-
cokinetic studies are also mandatory in the develop-
ment of phage and/or endolysin-based mastitis drugs.
Finally, in contrast to human medicine, phage 
therapy has not yet been incorporated into the Euro-
pean legislation for veterinary medicinal products. As 
registered veterinary medication based either on bac-
teriophages or on endolysins does not yet exist, their 
current therapeutic use is considered as a magistral 
preparation. This implicates that their use is justified 
for the individual treatment of an animal to avoid un-
necessary suffering, after prescription by a veterinar-
ian and preparation by a pharmacist. From the point 
of view of veterinary practice, this is not desirable 
because the dairy farmer cannot start therapy imme-
diately when detecting mastitis in one of his animals. 
Moreover, it does not make sense to apply individual 
mastitis therapy using a magistral preparation.
CONCLUSION
In conclusion, currently reported data clearly in-
dicate that bacteriophages and phage-derived endo-
lysins constitute a potential therapeutic alternative in 
the treatment of bovine mastitis. Nonetheless, these 
studies were predominantly carried out in a preclinical 
context. Further research should now evaluate wheth-
er this promising therapy is also active in the complex 
bovine mammary gland. If these results are confirmed, 
bacteriophages and phage-derived endolysins could 
indeed fulfil their promise by reducing 1. the exces-
sive use of antibiotics in the dairy industry and 2. the 
common antimicrobial resistance in mastitis-causing 
pathogens. Furthermore, this alternative treatment 
would also become an important strategy to counter-
act the antimicrobial resistance in human pathogens as 
viewed from the ‘One Health’ perspective.
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